Kawakami Tomotaka, Tanaka Atsushi, Negoro Shinichiro, Morisawa Yoshihiko, Mikami Masaki, Hojo Makoto, Yamamoto Takatsugu, Uegaki Satoko, Aiso Mitsuhiko, Kawasaki Takahiro, Ishii Taro, Kuyama Yasushi, Fukusato Toshio, Takikawa Hajime
Department of Medicine, Teikyo University School of Medicine, Tokyo.
Intern Med. 2007;46(14):1105-8. doi: 10.2169/internalmedicine.46.0086. Epub 2007 Jul 17.
We report a patient with primary hypothyroidism, who developed hepatocellular injury due to levothyroxine, synthetic thyroxine. A 63-year-old male was admitted to our hospital due to elevation of liver enzymes. The patient was diagnosed as having hypothyroidism and had been treated with levothyroxine for almost two months until admission. Drug-induced liver injury induced due to levothyroxine was suspected and liver enzymes were rapidly decreased after discontinuation of levothyroxine and dried thyroid powder, also containing thyroxine. Synthetic triiodothyronine, the deiodinated form of levothyroxine was administered instead, and was well tolerated by the patient. The drug-induced lymphocyte stimulation test (DLST) using levothyroxine was negative. Since triiodothyronine which structurally resembles levothyroxine did not cause liver injury, and DLST using levothyroxine was negative, it is unlikely that levothyroxine itself was targeted by the immune system. Rather, we assume that the complex of levothyroxine as the hapten and liver-related macromolecules in the body as the carrier might have acquired antigenicity in this patient and subsequently resulted in liver injury.
